Dimerix Net Debt per Share
The Net Debt per Share of Dimerix (DXB.AX) as of Sep 5, 2026 is -0.12 AUD. In the previous year, Net Debt per Share was -0.04 AUD — a change of 210.05% (lower).
Get this data via API
Financial Data API
Net Debt per Share
-0.12AUD
YoY
210.05%
Last updated:
Net Debt per Share of Dimerix is 2026 -0.12 AUD. Net Debt per Share of Dimerix was 2025 -0.04 AUD. It decreases by 210.05% lower compared to the previous year.
The Dimerix Net Debt per Share history
3 Years
10 Years
25 Years
Max
Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-0.01 AUD
Jan 1, 2019
-0.01 AUD
Jan 1, 2020
-0.01 AUD
Jan 1, 2021
-0.00 AUD
Jan 1, 2022
-0.02 AUD
Jan 1, 2023
-0.00 AUD
Jan 1, 2024
-0.04 AUD
Jan 1, 2025
-0.12 AUD
| YEAR | Net Debt per Share | YoY |
|---|---|---|
| -0.12AUD | +210.05% | |
| -0.04AUD | +981.21% | |
| -0.00AUD | -78.72% | |
| -0.02AUD | +5,987.07% | |
| -0.00AUD | -97.65% | |
| -0.01AUD | +87.79% | |
| -0.01AUD | -43.30% | |
| -0.01AUD | +179.99% | |
| -0.00AUD | +11.19% | |
| -0.00AUD | -31.13% | |
| -0.01AUD | +144.27% | |
| -0.00AUD | — |
Access this data via the Eulerpool API
Dimerix Stock analysis
What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Dimerix stock
Net Debt per Share of Dimerix is -0.12 AUD in 2026.
Net Debt per Share of Dimerix changed from -0.04 AUD to -0.12 AUD, representing a 210.05% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Net Debt per Share Dimerix since 2006 – with annual values, charts, and detailed analysis.
Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.
Access this data via the Eulerpool API
Other — Dimerix
All Key Metrics — Dimerix
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth